{"id":19371,"date":"2023-05-05T10:08:24","date_gmt":"2023-05-05T10:08:24","guid":{"rendered":"https:\/\/clinlabint.com\/?p=19371"},"modified":"2023-05-05T10:08:24","modified_gmt":"2023-05-05T10:08:24","slug":"tetra-pharm-technologies-launches-first-product-in-germany","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/tetra-pharm-technologies-launches-first-product-in-germany\/","title":{"rendered":"Tetra Pharm Technologies launches first product in Germany"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Tetra Pharm Technologies launches first product in Germany<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

The Danish biotech company, Tetra Pharm Technologies, is launching its first product, XATEPA\u00ae, on the German market. XATEPA\u00ae is a pain-relieving pharmaceutical\u00a0drug based on cannabinoids.<\/b><\/h3>\n

<\/p>\n

Tetra Pharm Technologies develops and manufactures pharmaceutical drugs targeting the endocannabinoid system for the treatment of neuropathic pain, sclerosis and mental health disorders.<\/p>\n<\/div><\/section>
\n

Tetra Pharm Technologies launches first product in Germany<\/div><\/div><\/div>
\n

“The launch of our first product represents an important and significant milestone for Tetra Pharm Technologies. From a business perspective, it gives us the opportunity to further strengthen the company’s long-term research and development efforts, which is our primary focus<\/i>“, says Martin Rose, Chief Executive Officer, Tetra Pharm Technologies.<\/p>\n

Tetra Pharm Technologies plans to expand sales of XATEPA\u00ae and launch the drug in a number of additional European and overseas markets in the near future.<\/p>\n

“The suitability of the drug delivery system is often neglected at the expense of cannabinoid bioavailability. Our XATEPA\u00ae sublingual spray is devised as a so-called enabling technology to provide optimal conditions for cannabinoid uptake and thus efficacy. From a pharmaceutical science perspective, we are indeed very proud of this achievement, and we look forward to launch more innovative products targeting the endocannabinoid system<\/i>“, says Dr. Morten Alles\u00f8, Chief Scientific Officer, Tetra Pharm Technologies.<\/p>\n

Tetra Pharm Technologies has entered into an agreement with PHOENIX Pharma-Einkauf GmbH\u00a0for the distribution of XATEPA\u00ae in Germany. PHOENIX Pharma-Einkauf GmbH\u00a0is one of Europe’s largest wholesale distributors of pharmaceutical and healthcare products.<\/p>\n

“Germany is the largest market in Europe for pharmaceutical drugs<\/i>\u00a0based on cannabinoids, and we have positive expectations for the sales of XATEPA\u00ae. The partnership with <\/i>PHOENIX Pharma-Einkauf GmbH\u00a0regarding distribution to German pharmacies ensures access to the product for all doctors and their patients, and since we have eliminated any middlemen, we can deliver the product at a fair price<\/i>“, says Martin Caspersen, Chief Commercial Officer, Tetra Pharm Technologies.<\/p>\n

For more information, please visit www.tetrapharm.eu<\/a><\/p>\n<\/div><\/section>
\n